Nový prístup k liečbe CML liekom s pridanou hodnotou // SOLEN

Onkológia 1/2025

A new approach to the treatment of CML with a value-added drug

Dasatinib, a tyrosine kinase inhibitor (TKI), is primarily used in the treatment of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL). Oral administration of dasatinib is convenient and promotes improved quality of patients‘ lives. However, it carries the risk of variable drug exposure which may translate into reduced drug efficacy or variable safety. Dasatinib in the form of dasatinib monohydrate exhibits pH-dependent solubility. To mitigate the pH dependence and exposure variability, a new formulation containing dasatinib anhydrate was developed. This formulation demonstrated improved absorption and less pharmacokinetic variability compared to dasatinib monohydrate, which may lead to better clinical outcomes.

Keywords: chronic myeloid leukaemia, tyrosine kinase inhibitors, dasatinib monohydrate, dasatinib anhydrate, gastric pH